Australian biotech market today 19.03.09

By Staff Writers
Thursday, 19 March, 2009

The Big Three dragged the pharma and biotech index on an otherwise good day for the All Ordinaries at 3pm today.

Cochlear, CSL and Resmed are all down today, Cochlear (ASX:COH) by 2.6 per cent and CSL (ASX:CSL) by almost six per cent after substantial shareholder Fidelity Investments sold a large parcel of shares.

Resmed (ASX:RMD) is down 2.9 per cent to just over $5.

Genera Biosystems (ASX:GBI) was up for the second day in a row, now trading at 32c, as was Novogen (ASX:NRT), which has released more detail about the mode of action of its anti-cancer compound NV-128. It rose almost 10c to 51c.

Starpharma (ASX:SPL) is up on interim data from a small clinical trial, while pSivida (ASX:PVA)had another 9c gain to trade over a dollar.

ChemGenex (ASX:CXS) was down 7c on very small volumes, IDT (ASX:IDT) was down 8c and Cellestis (ASX:CST) down 7c.

Acrux (ASX:ACR) was down a touch, as was Avexa (ASX:AVX) and Pharmaxis (ASX:PXS).

Related News

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd